Shimada H, Kamenosono T, Kawagoe M, Funakoshi T, Kiyozumi M, Takadate A, Kojima S
Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.
J Pharmacobiodyn. 1991 Oct;14(10):555-60. doi: 10.1248/bpb1978.14.555.
Sodium N-benzyl-D-glucamine dithiocarbamate (BGD), sodium N-p-hydroxymethylbenzyl-D-glucamine dithiocarbamate (HBGD), sodium N-p-carboxybenzyl-D-glucamine dithiocarbamate (CBGD), and sodium N-p-methoxybenzyl-D-glucamine dithiocarbamate (MeOBGD) were evaluated for their efficacy in the distribution and excretion of cadmium in rats exposed to cadmium. Rats were injected intraperitoneally with 109CdCl2 (1 mg Cd/kg and 74 kBq of 109Cd/one animal) and 30 min or 24 h later, they were injected with chelating agents (400 mumol/kg). At both 30 min and 24 h after treatment with cadmium, these chelating agents all significantly enhanced the biliary excretion of cadmium. At 24 h after cadmium injection, BGD and MeOBGD were the most effective on the biliary excretion of the metal. These chelating agents were effective in mobilizing cadmium from the liver at 30 min after cadmium treatment. At 24 h after cadmium treatment, BGD and MeOBGD significantly depressed cadmium content in the liver. In another experiment, rats were injected intraperitoneally with 109CdCl2 and 3 d later, they were injected with BGD, HBGD, or MeOBGD every other day for 2 weeks. The fecal excretion of cadmium was significantly increased by these chelating agents and MeOBGD was the most effective. The hepatic and renal cadmium contents were significantly decreased after BGD, HBGD or MeOBGD injection. The injection of MeOBGD to rats pretreated with cadmium was more effective than that of BGD, HBGD, or CBGD in removing cadmium from the liver. HBGD injection was more effective in decreasing the cadmium content in the kidney. The treatment with these chelating agents did not cause the redistribution of cadmium to brain, testes, and heart.
评估了N-苄基-D-葡糖胺二硫代氨基甲酸钠(BGD)、N-对羟甲基苄基-D-葡糖胺二硫代氨基甲酸钠(HBGD)、N-对羧基苄基-D-葡糖胺二硫代氨基甲酸钠(CBGD)和N-对甲氧基苄基-D-葡糖胺二硫代氨基甲酸钠(MeOBGD)对接触镉的大鼠体内镉分布和排泄的功效。给大鼠腹腔注射109CdCl2(1mg镉/千克体重且每只动物含74kBq的109Cd),30分钟或24小时后,给它们注射螯合剂(400μmol/千克体重)。在镉处理后的30分钟和24小时,这些螯合剂均显著增强了镉的胆汁排泄。在注射镉24小时后,BGD和MeOBGD对金属的胆汁排泄最有效。这些螯合剂在镉处理30分钟后能有效促使镉从肝脏中排出。在镉处理24小时后,BGD和MeOBGD显著降低了肝脏中的镉含量。在另一项实验中,给大鼠腹腔注射109CdCl2,3天后,每隔一天给它们注射BGD、HBGD或MeOBGD,持续2周。这些螯合剂显著增加了镉的粪便排泄,其中MeOBGD最有效。注射BGD、HBGD或MeOBGD后,肝脏和肾脏中的镉含量显著降低。给预先接触镉的大鼠注射MeOBGD在从肝脏中清除镉方面比BGD、HBGD或CBGD更有效。注射HBGD在降低肾脏中的镉含量方面更有效。用这些螯合剂进行治疗未导致镉重新分布至脑、睾丸和心脏。